FindTrial
Sign In

The observation of clinical changes in refractory patients with type 2 diabetes before and after using dapagliflozin

The observation of clinical changes when using dapagliflozin in type 2 diabetes patients having long course, receiving high doses of insulin and with diabetic nephropathy and poor glycemic control

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800014499
Enrollment
Unknown
Registered
2018-01-17
Start date
2018-01-26
Completion date
Unknown
Last updated
2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Self-control:using dapagliflozin

Sponsors

Tianjin Fourth Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: More than 10 years in the course of T2DM; With diabetic nephropathy, the scavenging rate of blood creatinine was normal; The liver function was normal; Daily insulin dosage=40u, must with Metformin;HbA1c=8%; without severe acute complications of diabetes; Consciousness is clear.

Exclusion criteria

Exclusion criteria: Gestational diabetes mellitus; Special type diabetes; Infectious diseases; Disorder of consciousness and patients who can not take care of themselves; Patients with severe cardiopulmonary insufficiency.

Design outcomes

Primary

MeasureTime frame
Amount of urine sugar;Urine protein;Urine micro albumin quantification;Uric acid quantitative;Blood electrolyte potassium sodium chloride.;Urine electrolyte;—

Secondary

MeasureTime frame
Blood uric acid;urine ph;—

Countries

China

Contacts

Public ContactHao Zhaohu

Tianjin Fourth Central Hospital

keddyhm@163.com+86 13672097031

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026